Sec Form 4 Filing - Brooks Michael J @ Edesa Biotech, Inc. - 2019-06-07

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Brooks Michael J 2. Issuer Name and Ticker or Trading Symbol Edesa Biotech, Inc. [ EDSA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President (Last) (First) (Middle) C/O EDESA BIOTECH INC., 100 SPY COURT 3. Date of Earliest Transaction (MM/DD/YY) 06/07/2019 (Street) MARKHAM, A6L3R 5H6 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 0.38 ( 1 ) 06/07/2019 A 128,753 ( 2 ) ( 3 ) ( 4 ) 08/28/2027 Common Shares 128,753 $ 0 128,753 D Stock Option (right to buy) $ 0.38 ( 1 ) 06/07/2019 A 22,934 ( 2 ) ( 3 ) ( 5 ) 09/26/2027 Common Shares 22,934 $ 0 22,934 D Stock Option (right to buy) $ 0.38 ( 1 ) 06/07/2019 A 1,529 ( 2 ) ( 3 ) ( 6 ) 12/28/2028 Common Shares 1,529 $ 0 1,529 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Brooks Michael J C/O EDESA BIOTECH INC. 100 SPY COURT MARKHAM, A6L3R 5H6 President Signatures /s/Michael S. Brooks 06/11/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )In Canadian currency. ( 2 )On June 7, 2019, Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) completed its share exchange transaction with Edesa Biotech Inc. ("Edesa") and the shareholder of Edesa pursuant to that certain Share Exchange Agreement, dated March 7, 2019. This option was issued in replacement of an option to purchase shares of Edesa. ( 3 )All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. ( 4 )This option was fully vested on 8/28/17. ( 5 )This option vests and becomes exercisable 1/3 on 9/26/18, and monthly thereafter through 9/26/20. ( 6 )This option vests and becomes exercisable 1/3 on 12/28/19, and monthly thereafter through 12/28/21.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.